Ranibizumab biosimilar FYB201

Ranibizumab biosimilar FYB201

Products

Information

Polpharma Biologics’ joint venture company, Bioeq, in collaboration with Formycon, is working on a Ranibizumab biosimilar, code named FYB201. FYB201 will be commercialized in the US by Coherus and by Teva Pharmaceutical Industries in Europe, Canada, Israel and New Zealand. Bioeq submitted a biologics license application (BLA) for Ranibizumab to the U.S. Food and Drug Administration in August 2021.
Polpharma BiologicsWe have developed an extensive and ever-growing pipeline of biosimilars to treat a number of conditions across major therapeutic areas. Many of these biosimilars have already been partnered, the most advanced of which are listed below. We consistently invest in the start of one biosimilar development per year based upon expert market analysis, clinical evaluation, and an extensive manufacturing assessment. The ultimate goal of our biosimilar development is to partner with companies that have the reach to maximize the access to patients who need such high-quality medicines. Biosimilars in our pipeline include Ranibizumab, Natalizumab, Tysabri, Vedolizumab, Ipilimumab, Ocrelizumab, Pembrolizumab, Nivolumab

Log in

See all the content and easy-to-use features by logging in or registering!